Objective-To test the hypothesis that chronic infusion of angiotensin-(1-7) [Ang-(1-7)] may dose-dependently inhibit atherosclerotic lesion formation by targeting vascular smooth muscle cells and a large dose of Ang-(1-7) may stabilize mature plaque by targeting macrophages. Approach and Results-In vivo, the effects of Ang-(1-7) on atherogenesis and plaque stability were observed in ApoE −/− mice fed a high-fat diet and chronic angiotensin II infusion. In vitro, the effects of Ang-(1-7) on vascular smooth muscle cells' proliferation and migration, and macrophage inflammatory cytokines were examined. Ang-(1-7) dosedependently attenuated early atherosclerotic lesions and inhibited vascular smooth muscle cells' proliferation and migration via suppressing extracellular regulated protein kinase/P38 mitogen-activated protein kinase and janus kinase/ signal transducers and activators of transcription activities and enhancing smooth muscle 22α and angiotensin II type 2 receptor expression. Ang-(1-7) treatment resulted in high contents of collagen and vascular smooth muscle cells, and low contents of macrophages and lipids in carotid mature plaques. Ang-(1-7) lowered the expression levels of proinflammatory cytokines and activities of matrix metalloproteinases in mature plaques. Ang-(1-7) treatment inhibits early atherosclerotic lesions and increases plaque stability in ApoE −/− mice, thus providing a novel and promising approach to the treatment of atherosclerosis. (Arterioscler Thromb Vasc Biol. 2013;33:1978-1985 
R ecent studies have found that angiotensin-converting enzyme-2 (ACE2), a new component of the renin-angiotensin system, exhibits potent effects on cleaving vasoconstrictive angiotensin II (Ang-II) into vasodilative angiotensin- (1) (2) (3) (4) (5) (6) (7) [Ang- (1) (2) (3) (4) (5) (6) (7) ] and thus provides a potential therapeutic target for Ang-II-related cardiovascular diseases. 1, 2 We have previously reported that exogenous ACE2 gene transfer markedly attenuated atherosclerotic lesions and administration of A779, an antagonist of Ang-(1-7), led to a large offset against the salutary effects of ACE2 overexpression, suggesting that Ang-(1-7) per se has an indispensable antiatherosclerotic efficacy. 3, 4 Current evidence shows that endothelial cells are the major target of Ang-(1-7) on the vascular wall, 5, 6 although the intracellular signaling pathways after Mas receptor (MasR) activation are only poorly understood. 7 A recent report found that the macrophages from ACE2 −/− mice exhibited enhanced expression of inflammatory cytokines, but this effect may be a result of decreased Ang-II levels and increased Ang-(1-7) levels. 8 Despite these research efforts, several key issues remain unsolved. First, because the half-life of Ang-(1-7) in vivo is very short 9 and a large dose of Ang-(1-7) may cause adverse effects, 10 the dose-response relationship between Ang-(1-7) and early atherosclerotic lesions needs to be clarified. Second, it is unclear whether Ang-(1-7) is capable of inhibiting early atherosclerotic lesion formation and stabilizing mature atherosclerotic plaques. Third, as proliferation and migration of vascular smooth muscle cells (VSMCs) are characteristic of early atherosclerotic lesions, whereas marked macrophage infiltration is a feature of vulnerable plaque, whether Ang-(1-7) exerts beneficial effects on these cells is to be defined. Finally, it has been reported that intracellular mitogen-activated protein kinases and janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling cascades play an essential role in the pathogenesis of Ang-II-mediated vascular diseases 11 , and smooth muscle 22α (SM22α), a novel cytoskeletal protein, is critical in modulating VSMCs phenotype. 12 However, the relationship between Ang-(1-7) and these signaling molecules is obscure. To address these important issues, we hypothesize that chronic infusion of Ang-(1-7) may dose-dependently inhibit atherosclerotic lesion formation by targeting VSMCs via the Mas-extracellular regulated protein kinase/P38 mitogen-activated protein kinase (ERK/P38)-SM22α and JAK/ STAT pathway, and a large dose of Ang-(1-7) may stabilize mature plaque by targeting macrophages and inhibiting local inflammation and extracellular matrix degradation. In the present study, we performed a series of in vitro and in vivo experiments to validate this hypothesis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Body Weight, Blood Pressure, and Serum Lipid Profile
At the end of the first part (8 weeks) and the second part (10 weeks) of the in vivo study, both systolic and diastolic blood pressures were substantially increased in comparison with the baseline blood pressure measurements (data not shown). However, no significant differences were found in body weight, blood pressure, and serum lipid levels among vehicle-treated, Ang-(1-7)-treated and Ang-(1-7)+A779-treated groups, indicating that chronic infusion of Ang-(1-7) or A779 had no significant effects on these parameters ( Table I in In ApoE −/− mice without Ang-II infusion, blood pressure levels were not statistically different among vehicle-treated, Ang-(1-7)-treated, and Ang-(1-7)+A779-treated groups ( Figure 1 ; Table II in the online-only Data Supplement).
Aortic Lesion Formation
In the first part of the in vivo study, the relative en face lesion area of the aorta arches was dose-dependently decreased in the Ang-(1-7)-treated subgroups. However, only the difference between the large dose of Ang-(1-7) subgroup and the vehicle-treated group reached a statistical significance. The antiatherosclerosis effect of Ang-(1-7) was significantly reversed by coadministration of A779 (Figure 2A and 2B) . Similarly, the relative cross-sectional area of the aortic lesion also showed a dose-dependent decrease in the Ang-(1-7)treated subgroups but only the difference between the large dose of Ang-(1-7) subgroup and the vehicle-treated group was significant. Again, A779 largely reversed the beneficial effects of Ang-(1-7) on atherosclerosis (Figure 2A and 2C) . These results indicate that a large dose of Ang-(1-7) may inhibit atherosclerotic lesion formation, whereas A779 may abolish these salutary effects.
VSMCs' Proliferation and Migration
VSMCs' proliferation ( Figure 2D and 2E) and migration ( Figure 2F and 2G) were markedly increased in the Ang-IItreated group compared with the vehicle-treated group but was normalized in the Ang-II+Ang-(1-7)-treated group. However, administration of A779 in the Ang-II+Ang-(1-7)+A779treated group led to a similar increase in VSMCs' proliferation and migration as in the Ang-II-treated group. In contrast, there was no significant difference in VSMCs' proliferation and migration between the Ang-(1-7)-treated group and the vehicle-treated or A779-treated groups. These results suggest that Ang-II treatment may enhance VSMCs' proliferation and migration, whereas the additional administration of Ang-(1-7) may offset the adverse effects of Ang-II on VSMCs.
In the first part of the in vivo study, the relative expression of proliferating cell nuclear antigen (PCNA), in the aortic plaque assayed by immunofluorescence staining, in the Ang-(1-7)-treated group was significantly lower than in the vehicle-treated group, which was aborted by coadministration of A779 ( Figure 2H and 2I).
ERK/P38 and JAK/STAT Activities
ERK/P38 and JAK/STAT activities measured in vitro by
Western blot was higher in the Ang-II-treated group than in the vehicle-treated group but was normalized in the Ang-II+Ang-(1-7)-treated group. However, ERK/P38 and JAK/ STAT activities were increased again in the Ang-II+Ang-(1-7)+A779-treated group. However, there was no significant difference in ERK/P38 and JAK/STAT activities between the vehicle-treated group and the Ang-(1-7)-treated or A779treated groups ( Figure 3A and 3C). These results suggest that Ang-II treatment may enhance ERK/P38 and JAK/STAT phosphorylation levels, whereas administration of Ang-(1-7) may abolish the effects of Ang-II on ERK/P38 and JAK/ STAT activities.
Then we examined the effects of chronic infusion of Ang-(1-7) on ERK/P38 and JAK/STAT activities in vivo. The results showed that ERK/P38 and JAK/STAT activities measured by Western blot were dramatically decreased in the Ang-(1-7)treated group relative to the vehicle-treated group, which was largely reversed by A779 treatment (Figure 3B and 3D).
SM22α Expression
SM22α protein expression levels in VSMCs assessed by Western blot were lower in the Ang-II-treated group than in the vehicle-treated group but were normalized in the Ang-II+Ang-(1-7)-treated group. However, SM22α expression levels were declined again in the Ang-II+Ang-(1-7)+A779treated group. Surprisingly, SM22α protein expression was increased by >2-fold in Ang-(1-7)-treated group compared with the vehicle-treated group ( Figure 3A and 3C). To further disclose the relationship between ERK/P38 signaling pathway and SM22α, we used PD98059, a specific inhibitor of ERK phosphorylation and SB203580, a specific inhibitor of P38 phosphorylation after Ang-II stimulation. SM22α protein expression levels of VSMCs were higher after PD98059 or SB203580 treatment and the combination of PD98059 and SB203580 further increased SM22α protein expression levels ( Figure IA and IB in the online-only Data Supplement). These results indicate that Ang-II treatment may decrease, whereas Ang-(1-7) treatment or use of ERK or P38 signaling antagonists may increase SM22α protein expression levels. In vivo, the SM22α protein expression level measured by immunohistochemical staining was much higher in the Ang-(1-7)-treated group than in the vehicle-treated or Ang-(1-7)+A779-treated groups ( Figure 3E and 3F), suggesting that chronic infusion of Ang-(1-7) may enhance SM22α protein expression in the aortic media of ApoE −/− mice, whereas A779 attenuated the effect of Ang-(1-7) on SM22α protein expression.
Matrix Metalloproteinases mRNA Expression in VSMCs
The mRNA expression levels of matrix metalloproteinase (MMP)-2 and MMP-9 were higher in the Ang-II-treated group than in the vehicle-treated group but were normalized in the Ang-II+Ang-(1-7)-treated group. However, the addition of A779 further increased the mRNA expression levels of MMP-2 and MMP-9 ( Figure 
AT1R, AT2R, and MasR Expression In Vivo and In Vitro
In the first part of the in vivo study, the mRNA expression levels of AT1R and MasR in the aortic plaque showed no significant difference among the vehicle-treated group, Ang-(1-7)-treated group, and Ang-(1-7)+A779-treated group. However, the mRNA expression level of angiotensin II type 2 receptor (AT2R) was increased in the Ang-(1-7)-treated The mRNA expression levels of AT1R and MasR in VSMCs assessed by real-time quantitative polymerase chain reaction did not differ among the vehicle-treated, Ang-(1-7)-treated, and Ang-(1-7)+A779-treated groups. However, the AT2R mRNA expression was higher in the Ang-(1-7)-treated group than in the vehicle-treated and Ang-(1-7)+A779-treated groups ( Figure IIIB 
Carotid Plaque Components
In the second part of the in vivo study, the relative contents of the carotid plaque components were assessed by immunohistochemistry. The relative contents of lipids and macrophages were lower in the Ang-(1-7)-treated group. In contrast, the relative contents of VSMCs and collagen were higher in the Ang-(1-7)-treated group than in the vehicle-treated groups.
These beneficial effects were largely offset by combined treatment with A779 ( Figure 4A and 4B) .The calculated plaque vulnerability index was lower in the Ang-(1-7)-treated group than in the vehicle-treated group or Ang-(1-7)+A779-treated group. These results demonstrate that chronic infusion of Ang-(1-7) enhances plaque stability which is largely reversed by combined infusion of A779 ( Figure 4C ).
Macrophage Phenotype and Cytokine Secretion
In the second part of the in vivo study, flow cytometry showed that the ratio of type M2 to type M1 macrophages in the peritoneal cavities of Ang-(1-7)-treated mice was higher than in the vehicle-treated group or Ang-(1-7)+A779-treated group (Figure 5A and 5B) . Furthermore, the reverse transcription polymerase chain reaction results showed a concomitant upregulation of M2-related genes (Arg-1 and chemokine [CC motif] ligand 9) and a significant downregulation of M1-related genes (CD86 and inducible nitric oxide synthase [iNOS]; Figure 5C ). In contrast, the protein expression levels of interleukin-6, tumor necrosis factor-α, and membrane cofactor protein-1 in the carotid plaque were lower in the Ang-(1-7)-treated group than in the vehicle-treated group or Ang-(1-7)+A779-treated group (Figure 5D and 5E ). Furthermore, we examined the effects of Ang-(1-7) and A779 on the protein expression levels of interleukin-6, tumor necrosis factor-α, and membrane cofactor protein-1 in RAW264.7 mouse macrophages. The protein expression levels of these cytokines showed a remarkable increase in the Ang-II-treated group but were normalized in the Ang-(1-7)-treated group relative to the vehicle-treated group. The addition of A779 led to a sharp increase in the expression levels of these cytokines in the Ang-II+Ang-(1-7)+A779-treated group. However, there was no significant difference in the expression levels of these cytokines among the vehicle-treated, Ang-(1-7)-treated, and A779-treated groups ( Figure 5F and 5G) . These results indicate that Ang-(1-7) attenuates plaque inflammation and cytokine secretion from macrophages induced by Ang-II but these effects are abolished by combined administration of A779.
MMPs' Expression and Activity In Vivo and In Vitro
In the third part of the in vivo study, the protein expression levels of MMP-2 and MMP-9 in the aortic plaque were markedly lower in the Ang-(1-7)-treated group than in the vehicle-treated group or the Ang-(1-7)+A779-treated group (Figure 6A and 6B) . Similarly, pro-MMP-2, MMP-2, pro-MMP-9, and MMP-9 activities assessed by zymography were remarkably lower in the Ang-(1-7)-treated group than in the vehicle-treated group. When the Ang-(1-7) was coadministered with A779, the effects of Ang-(1-7) on MMPs were reversed. These results suggest that Ang-(1-7) decreases MMP-2 and MMP-9 expression and activities in vivo, whereas A779 attenuates these effects ( Figure 6C and 6D ). Furthermore, we investigated the effects of Ang-(1-7) and A779 on the mRNA expression levels of MMP-2 and MMP-9 in RAW264.7 mouse macrophages. The mRNA expression levels of MMP-2 and MMP-9 showed a remarkable increase in the Ang-II-treated group but were normalized in the Ang-(1-7)-treated group in comparison with the vehicle-treated group. However, the addition of A779 led to a remarkable increase in the expression levels of MMP-2 and MMP-9 in the Ang-II+Ang-(1-7)+A779-treated group ( Figure 6E ).
Histology of the Heart and Kidney
In the first part of the in vivo study, the relative content of collagen ( Figure IVA and IVC in the online-only Data Supplement) in the myocardium and that of macrophages in the kidney ( Figure IVB and IVD in the online-only Data Supplement) were lower in the Ang-(1-7)-treated group than in the vehicle-treated group or Ang-(1-7)+A779-treated group.
Discussion
The major finding of the present study was that (1) chronic Ang-(1-7) infusion dose-dependently inhibited early atherosclerotic lesion formation via suppressing VSMCs' proliferation and migration; (2) chronic infusion of a large dose of Ang-(1-7) enhanced mature plaque stability via reducing type M1 macrophages and inhibiting inflammatory cytokine expression and MMPs activities; (3) Ang-(1-7) exerted its beneficial effects via MasR and possibly AT2R; (4) the molecular mechanisms underlying these beneficial effects may involve attenuated ERK/P38 and JAK/STAT signaling pathways and enhanced SM22α expression. To the best of our knowledge, our study has provided for the first time the experimental evidence of the therapeutic effects and related mechanisms of Ang-(1-7) in the treatment of atherosclerosis.
Current evidence indicates that Ang-II receptor antagonists are effective in attenuating atherosclerotic lesions. However, it remains unclear whether Ang-(1-7) treatment is able to counteract Ang-II-induced atherosclerosis. To clarify the dose-response relationship between Ang-(1-7) and early atherosclerotic lesions, 3 infusion doses of Ang-(1-7) were used by referring to previous studies. 13, 14 To our surprise, only a large dose of Ang-(1-7) was able to attenuate the aortic lesions without significant impact on blood pressure likely because of the following reasons: first, Ang-(1-7) was proved to decrease peripheral arterial resistance by ≈26%, while increasing cardiac output by ≈17% in rats 15, 16 ; second, recent studies found that Ang-(1-7) has a high affinity with MasR and a weak affinity with AT1R and AT2R, 17 and Ang-(1-7) lowered blood pressure only when it was used in combination with candesartan in spontaneous hypertensive rats. 18 These results suggest that AT1R-mediated vasoconstriction may to some extent attenuate MasR-and AT2R-mediated vasodilatation. To address the safety issue, we examined possible histological changes in the myocardium and kidney induced by chronic infusion of a large dose of Ang-(1-7) and found no adverse effects on these organs in our ApoE −/− mice. As Ang-(1-7) is physiologically antagonistic to Ang-II, Ang-(1-7) treatment should be beneficial wherever the tissue levels of Ang-II are increased, such as in the setting of atherosclerosis, diabetic nephropathy, and diabetic cardiomyopathy. 19, 20 A recent study reported that Ang-(1-7) treatment may attenuate atherosclerosis by targeting endothelial cells. 21 However, little is known about the role of Ang-(1-7) in VSMCs proliferation and migration, which is crucial during atherosclerotic lesion formation. 22, 23 The present study demonstrated that chronic infusion of a large dose of Ang-(1-7) substantially attenuated the aortic atherosclerotic lesions and inhibited VSMCs proliferation and migration. As Ang-II stimulates VSMCs proliferation and migration via the mitogen-activated protein kinases pathway, 11 we examined the effect of Ang-(1-7) on Ang-II-mediated ERK/P38 activation. Our results showed that Ang-(1-7) markedly inhibited Ang-II-enhanced ERK/P38 activities, which lent support to a recent report. 7 However, A779 treatment almost abolished the inhibitory effect of Ang-(1-7) on Ang-II-enhanced ERK/P38 activities, confirming that Ang-(1-7) counteracted the Ang-II pathway via the MasR. In view of the recent finding that SM22α plays a critical role in inhibiting VSMCs' proliferation and migration during atherogenesis, 12 we further examined the relationship among Ang-(1-7), ERK/P38, and SM22α and found that SM22α expression was remarkably increased by administration of Ang-(1-7), as well as by inhibition of ERK and P38 in VSMCs, suggesting that SM22α is an important downstream signaling molecule in the Ang-(1-7)-Mas-ERK/P38-SM22α pathways in VSMCs. In addition, our results revealed that Ang-(1-7) significantly inhibited Ang-II-enhanced JAK/ STAT activities, suggesting that JAK/STAT pathway may be involved in the effects of Ang-(1-7) on VSMCs' proliferation and migration. More importantly, these primary findings in VSMCs were confirmed by our in vivo experiments. These results revealed 2 novel pathways of Ang-(1-7)-Mas-ERK/ P38-SM22α and Ang-(1-7)-Mas-JAK/STAT that regulate the salutary effects of Ang-(1-7) on atherogenesis.
Previous studies found that deletion of AT2R was associated with exaggerated atherosclerosis in ApoE −/− mice. 24 In the current study, Ang-(1-7) treatment upregulated AT2R expression without altering AT1R or MasR expression, suggesting that AT2R may play a role in Ang-(1-7)-induced antiatherosclerotic effects. However, as the binding affinity of Ang-(1-7) to AT2R is much weaker than that of Ang-II to AT2R, 17 MasR is probably responsible for the majority of the antiatherosclerosis effects of Ang- (1) (2) (3) (4) (5) (6) (7) . Further studies are required to clarify whether inhibition of AT2R may abolish the salutary effects of Ang-II treatment.
Pathological studies in human have demonstrated that the plaque components rather than lesion size play a key role in the development of acute coronary syndrome, and vulnerable plaque is characterized by increased contents of macrophages and lipids and reduced contents of collagen and VSMCs. 25 Thus, the plaque vulnerability index has been recognized as a histological marker of vulnerable plaque. 26 In the present study, we examined the effect of chronic infusion of a large dose of Ang-(1-7) on the composition of the carotid plaques in ApoE −/− mice, and found that Ang-(1-7) treatment resulted in a significant decrease in macrophages and lipids whereas a substantial increase in collagen and VSMCs in the aortic and carotid plaques. In contrast, combined administration of Ang-(1-7) and A779 attenuated the plaque-stabilizing effects of Ang-(1-7). Recent studies showed that type M1 macrophages are a major player in plaque inflammation and progression, 27 and we found that the relative contents of type M1 macrophages were markedly reduced in the peritoneal cavities of Ang-(1-7)-treated mice. Thus, Ang-(1-7) treatment remarkably decreased the plaque vulnerability index in carotid plaques, indicating that Ang-(1-7) is a powerful cytokine for altering plaque components toward a stable plaque phenotype.
Another important finding of this study was that Ang-(1-7) treatment led to a dramatic reduction of the expression levels of interleukin-6, tumor necrosis factor-α, and membrane cofactor protein-1 in the aortic plaques, as well as in the macrophages, which was reversed by combined infusion of A779. Apart from inflammatory cytokines, macrophages or foam cells in plaques may also secrete proteolytic enzymes, such as MMPs, which may digest the extracellular matrix and weaken the fibrous cap. 28 Our results showed that Ang-(1-7) treatment dramatically inhibited MMP-2 and MMP-9 protein expression in plaques. Zymography assay further confirmed the efficacy of Ang-(1-7) in downregulating MMPs activities. The increased contents of collagen and VSMCs in the aortic and carotid plaques after Ang-(1-7) treatment may stem from the remarkable decrease of inflammatory cytokines and MMPs in these lesions. These results suggest that the major mechanisms underlying the plaque-stabilizing effects of Ang-(1-7) are reduction of type M1 macrophages and inhibition of inflammatory cytokines and MMPs.
In conclusion, Ang-(1-7) dose-dependently inhibited early atherosclerotic lesions via suppressing VSMCs' proliferation and migration, and a large dose of Ang-(1-7) enhanced plaque stability via inhibiting plaque inflammation and MMPs' expression and activities. The mechanisms underlying these effects may involve interaction between MasR and AT2R, attenuated ERK/P38 and JAK/STAT signaling pathways, and enhanced SM22α expression. Thus, Ang-(1-7) may provide a novel and promising approach to the treatment of atherosclerosis.
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